Prohibition Partners' North American Cannabis Report: Second Edition

Wednesday, 24 March 2021, 21:29:28
The North American cannabis industry saw significant developments in 2020, which is expected to continue throughout 2021. There has been an increase in investment due to the US 2020 election outcomes as all cannabis ballots in Arizona, Mississippi, New Jersey, Montana and South Dakota passed. Alongside the cannabis ballots, President Joe Biden and Vice President Kamala Harris have been inaugurated into the White House, and the traditionally cannabis-friendly Democrats have substantial control over Congress. These developments have issued a wave of hope that the US will likely see federal cannabis reform soon. With all the positive news surrounding the US cannabis industry, public cannabis companies such as Tilray, Cronos Group and Canopy Growth have seen a significant surge in their share price in the last two months. Although 2020 was a slow year for the public markets as the COVID-19 pandemic severely impacted cannabis companies and the expected mergers and acquisitions failed to materialise.
— Benzinga

Cronos Group Inc. (NASDAQ:CRON) Director Sells $7,197,623.13 in Stock

Sunday, 21 March 2021, 09:14:45
Cronos Group Inc. (NASDAQ:CRON) Director Jason Marc Adler sold 714,759 shares of the stock in a transaction on Wednesday, March 17th. The shares were sold at an average price of $10.07, for a total value of $7,197,623.13. Following the completion of the transaction, the director now owns 8,165,072 shares of the company’s stock, valued at […]
— Watchlist News

BMO Capital Stick to Their Hold Rating for Cronos Group By Investing.com

Wednesday, 17 March 2021, 10:05:49
BMO Capital Stick to Their Hold Rating for Cronos Group
— Investing.com

Organigram soars 47% after British American Tobacco invests $177 million in the cannabis producer

Thursday, 11 March 2021, 15:50:49
Summary List Placement Organigram stock spiked as much as 47% on Thursday after British American Tobacco invested in the cannabis producer. BAT will invest $176 million in Organigram for a 19.9% equity stake in the Canadian-based firm. Both companies have entered into a collaboration agreement in which they will develop next generation CBD products. Sign up here for our daily newsletter, 10 Things Before the Opening Bell . Shares of Organigram soared as much as 47% on Thursday after British American Tobacco invested $176 million into the Canada-based cannabis producer for a 19.9% equity stake in the firm. The strategic investment will accelerate Organigram's research and development and product pipeline development, with both companies entering into a product collaboration agreement. The two firms' first collaborative product venture will be in the CBD space. Both companies will contribute scientists, researchers, and product developers to the collaborative product initiative. The cash infusion into Organigram will also strengthen its balance sheet and put the company in a better position to compete in US markets. “[The deal] is instrumental in advancing our commitment to offering consumers innovative cannabis products and to furthering our long-term international strategy, ” CEO Greg Engel said in a press release.
— Business Insider Markets

Cannabis Investors: Should You Buy Cronos (TSX:CRON) Stock Right Now?

Thursday, 4 March 2021, 14:00:55
Here's why investing in Cronos stock is still a risky proposition. The post Cannabis Investors: Should You Buy Cronos (TSX:CRON) Stock Right Now? appeared first on The Motley Fool Canada .
— The Motley Fool Canada